Global Fund Pharmacovigilance Project
OverviewEstablishing a strong medicine safety monitoring system, also known as pharmacovigilance, is essential to protecting patients and ensuring the safe rollout of innovative medicines, treatments, and immunizations. However, pharmacovigilance systems in low- and middle-income countries remain insufficient. MSH has long worked to combat this disparity, specifically through the USAID-funded MTaPS program, and is building on these efforts to strengthen the pharmaceutical sector, with support from the Global Fund.
The Global Fund Pharmacovigilance Project enhanced pharmacovigilance in three priority countries—Cameroon, Mozambique, and Senegal—by equipping them with the support and resources they needed to monitor, detect, and assess the adverse effects of medicines. In collaboration with local ministries of health, MSH provided technical assistance to improve the countries’ regulatory practices in preparation for the introduction of new health products to combat HIV, tuberculosis, and malaria.
The project’s multifaceted approach to promoting robust pharmacovigilance systems included:
- Developing and improving legal frameworks and regulations that promote pharmacovigilance implementation and adherence
- Streamlining organizational structures and communication networks
- Increasing human resource capacity
- Instituting regulatory processes that follow global best practices
- Enhancing IT infrastructure for pharmacovigilance reporting and digitalization of activities
Explore our Impact
No posts found for the selected CPT Sources.